User login
VIENNA – The survival benefit shown by nivolumab in the phase III CheckMate 025 trial may offer hope of even longer survival benefits in advanced kidney cancer.
During a press briefing at the European Cancer Congress, study author Dr. Padmanee Sharma of the University of Texas MD Anderson Cancer Center in Houston, defended immune checkpoint inhibitor nivolumab’s 5.6-month gain in overall survival.
“The immune checkpoint therapy agents are targeting your immune system,” Dr. Sharma explained in an interview. “Your immune system has the capability of giving you a memory response.” That could lead to long-term, durable responses in cancer patients that can last for years, she noted.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @pwendl
VIENNA – The survival benefit shown by nivolumab in the phase III CheckMate 025 trial may offer hope of even longer survival benefits in advanced kidney cancer.
During a press briefing at the European Cancer Congress, study author Dr. Padmanee Sharma of the University of Texas MD Anderson Cancer Center in Houston, defended immune checkpoint inhibitor nivolumab’s 5.6-month gain in overall survival.
“The immune checkpoint therapy agents are targeting your immune system,” Dr. Sharma explained in an interview. “Your immune system has the capability of giving you a memory response.” That could lead to long-term, durable responses in cancer patients that can last for years, she noted.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @pwendl
VIENNA – The survival benefit shown by nivolumab in the phase III CheckMate 025 trial may offer hope of even longer survival benefits in advanced kidney cancer.
During a press briefing at the European Cancer Congress, study author Dr. Padmanee Sharma of the University of Texas MD Anderson Cancer Center in Houston, defended immune checkpoint inhibitor nivolumab’s 5.6-month gain in overall survival.
“The immune checkpoint therapy agents are targeting your immune system,” Dr. Sharma explained in an interview. “Your immune system has the capability of giving you a memory response.” That could lead to long-term, durable responses in cancer patients that can last for years, she noted.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @pwendl
AT THE EUROPEAN CANCER CONGRESS
